Pt(Iv) prodrugs with nsaids as axial ligands
A chemo-anti-inflammatory strategy is of interest for the treatment of aggressive cancers. The platinum (IV) prodrug with non-steroidal anti-inflammatory drugs (NSAIDs) as axial ligands is designed to efficiently enter tumor cells due to high lipophilicity and release the cytotoxic metabolite and NSAID intracellularly, thereby reducing side effects and increasing the therapeutic efficacy of platinum chemotherapy. Over the last 7 years, a number of publications have been devoted to the design of such Pt(IV) prodrugs in combination with anti-inflammatory chemotherapy, with high therapeutic efficacy in vitro and In vivo. In this review, we summarize the studies devoted to the development of Pt(IV) prodrugs with NSAIDs as axial ligands, the study of the mechanism of their cytotoxic action and anti-inflammatory activity, the structure–activity ratio, and therapeutic efficacy.
Citations by journals
1
2
3
4
5
6
|
|
Dalton Transactions
|
Dalton Transactions
6 publications, 17.14%
|
Journal of Medicinal Chemistry
|
Journal of Medicinal Chemistry
4 publications, 11.43%
|
International Journal of Molecular Sciences
|
International Journal of Molecular Sciences
3 publications, 8.57%
|
Pharmaceutics
|
Pharmaceutics
3 publications, 8.57%
|
Inorganics
|
Inorganics
2 publications, 5.71%
|
Molecules
|
Molecules
2 publications, 5.71%
|
European Journal of Medicinal Chemistry
|
European Journal of Medicinal Chemistry
2 publications, 5.71%
|
Analytical Chemistry
|
Analytical Chemistry
1 publication, 2.86%
|
ACS applied materials & interfaces
|
ACS applied materials & interfaces
1 publication, 2.86%
|
Cancers
|
Cancers
1 publication, 2.86%
|
ChemPhysChem
|
ChemPhysChem
1 publication, 2.86%
|
International Journal of Nanomedicine
|
International Journal of Nanomedicine
1 publication, 2.86%
|
Cancer Chemotherapy and Pharmacology
|
Cancer Chemotherapy and Pharmacology
1 publication, 2.86%
|
Chemistry - A European Journal
|
Chemistry - A European Journal
1 publication, 2.86%
|
Russian Chemical Bulletin
|
Russian Chemical Bulletin
1 publication, 2.86%
|
Russian Chemical Reviews
|
Russian Chemical Reviews
1 publication, 2.86%
|
Applied Sciences (Switzerland)
|
Applied Sciences (Switzerland)
1 publication, 2.86%
|
Coordination Chemistry Reviews
|
Coordination Chemistry Reviews
1 publication, 2.86%
|
New Journal of Chemistry
|
New Journal of Chemistry
1 publication, 2.86%
|
Journal of Molecular Structure
|
Journal of Molecular Structure
1 publication, 2.86%
|
1
2
3
4
5
6
|
Citations by publishers
2
4
6
8
10
12
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
12 publications, 34.29%
|
Royal Society of Chemistry (RSC)
|
Royal Society of Chemistry (RSC)
7 publications, 20%
|
American Chemical Society (ACS)
|
American Chemical Society (ACS)
6 publications, 17.14%
|
Elsevier
|
Elsevier
4 publications, 11.43%
|
Wiley
|
Wiley
2 publications, 5.71%
|
Springer Nature
|
Springer Nature
2 publications, 5.71%
|
Dove Medical Press
|
Dove Medical Press
1 publication, 2.86%
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 2.86%
|
2
4
6
8
10
12
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.